Creating therapies with macrocycles could spur biologics development

02/14/2013 | Xconomy

Comparatively few biologic drugs are making it to the market, and many of those are for rare diseases, writes Nick Terrett, chief science officer at Ensemble Therapeutics. Part of the reason is the difficulty of developing biologic drugs, but the industry could use a paradigm shift in how it develops drugs, Terrett writes. Combining small-molecules and biologics could create a new therapy option, the macrocycle, he writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA